3Settimana·

Long-term potential Hims & Hers

$HIMS (-2,57%)


It is relatively simple, $HIMS (-2,57%) should be judged as a rapidly growing telemedicine platform that enables healthcare delivery in the most convenient and compelling way.


$HIMS (-2,57%) GLP1 was already growing strongly before GLP1 and will, in my opinion, continue to develop and expand as one of the largest and leading telemedicine platforms.


A platform and brand designed to provide affordable access to medical care and products.


A personalized medical companion with tailored treatments for every need.


A vertically integrated, AI-powered platform with in-house compounding and testing.


You should tune out the short-term noise and wear noise protection if necessary 😁, the long-term potential and adoption of the platform and products is undeniable.


This graphic illustrates this very well:

attachment

$HIMS (-2,57%)
$NOVO B (-2,4%)
$LLY (-3,01%)
$XDWH (-0,69%)

37
6 Commenti

immagine del profilo
My nerves are a little calmer 🫶🏻
10
immagine del profilo
@Shem_sen 😂 $HIMS can't do without it either, price movements of over 20% are now the order of the day
3
immagine del profilo
I have a little toe in, looks pretty stable at 36€ at the moment
1
immagine del profilo
@Artiskon I also speculated on this yesterday at 38 🤷‍♂️😂
immagine del profilo
We love
1
2Settimana
GLP products make up a large part of sales, don't they?
Respective special approval was withdrawn and the cooperation with Novo was terminated.
How do you see this? How can Hims continue to sell GLP products?
Partecipa alla conversazione